We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

High Circulating Tumor Cell Levels Predict Rapid Progression of Metastatic Breast Ca

Oct 1, 2004
Volume: 
13
Issue: 
10
  • Breast Cancer

NEW ORLEANS—By monitoring the levels of circulating tumor
cells (CTCs) in peripheral blood, it is possible to predict which patients
with metastatic breast cancer will progress rapidly while on apparently futile
therapy, Daniel F. Hayes, MD, of the University of Michigan Comprehensive
Cancer Center, Ann Arbor, said at the 40th Annual Meeting of the American
Society of Clinical Oncology (abstract 509).

Results from a prospective multicenter study showed, by
multivariate analysis, that the level of CTCs at baseline was the strongest
and most significant predictor of a poor outcome, including progression-free
and overall survival. "Patients with 5 CTC/7.5 mL of blood or higher at the
first follow-up appear to be on futile therapy," Dr. Hayes noted.

The study enrolled 177 breast cancer patients prior to
treatment for metastatic disease at 20 treatment sites. The study also
included more than 200 healthy age- and sex-matched volunteers.

In 7.5 mL of blood collected from the subjects, the CTCs
were immunomagnetically separated based on EpCAM binding. After multicolor
fluorescent labeling, cells were classified by microscopy as CTCs if they
stained positive for both DAPI and cytokeratin 8, 18, and/or 19, and if they
stained negative for CD45. Clinical outcomes were determined by the
participating clinical sites without knowledge of CTC levels.

The study first gathered data from a "training set"
involving 102 patients, which established that 5 CTC/7.5 mL blood or greater
was the optimal cutoff to best distinguish rapid from more indolent
progression. The remaining 75 patients were then used as the validation set.
Blood was drawn every month for testing, and full assessments (including body
imaging) were made at baseline and at 3 and 6 months.

Elevated CTCs at baseline (5 CTCs or more) was documented
in 87 patients (49%), and 30% of all patients at first follow-up (usually 3 to
4 weeks after starting therapy) had persistent or newly elevated levels (see
Figure
). "CTC levels at first follow-up were usually reduced, compared
to baseline, a result we believe is due to the beneficial effects of therapy,"
Dr. Hayes explained.

The existence at baseline of 5 CTCs or more was
significantly associated with very short progression-free survival (2.7 months
vs 7.0 months for patients with less than 5 CTCs at baseline) and very short
overall survival (10.1 vs 18+ months) (P = .0001 for both comparisons).
At first follow-up, presence of 5 CTCs or more was also associated with very
short progression-free survival (2.1 months vs 7.0 months for those with less
than 5 CTCs at first follow-up) and overall survival (8.2 vs 18+ months) (P
= .0001 for both comparisons). The progression-free and overall survival in
the training set and the prospective validation set were "remarkably" similar,
Dr. Hayes noted.

In a multivariate analysis, the presence of 5 CTCs or more
at baseline was the most powerful predictor of outcome and was independently
prognostic for both progression-free survival (hazard ratio [HR] 1.76) and
overall survival (HR 4.26). For those with 5 CTCs or more at first follow-up,
these hazard ratios were 2.52 and 6.49, respectively, both highly significant.
[For full results of the study, see N Engl J Med 351:781-791, 2004.]

Dr. Hayes concluded, "Fifty percent of patients with
metastatic disease who have recently progressed and are about to start a new
therapy have elevated CTCs at baseline. These patients have substantially and
significantly shorter progression-free and overall survival."

Perhaps more importantly, he said, "a fraction of these
patients convert to low CTC levels fairly rapidly, and their prognosis is
relatively favorable. However, the 30% whose CTC levels become or remain at 5
CTC/7.5 mL or higher at first follow-up have a very short progression-free
survival and overall survival, and appear to be on futile therapy."

He said that the laboratory test for measuring CTCs has
recently been approved by the FDA. While it could be useful in clinical
decision-making in regard to patients who are not responding well to
treatment, he believes that randomized controlled trials soon to be conducted
will help answer whether switching therapy in patients with elevated CTCs at 3
to 4 weeks will improve prognosis. 


Related Articles

  • Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast Cancer
  • Forecasting PARP Inhibitor Resistance in Breast Cancer Patients
  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.